Neurocrine Biosciences, Inc. reported additional results from the Phase 3 KINECT-HD study investigating valbenazine for the treatment of chorea associated with Huntington Disease (HD). In December 2021, Neurocrine previously reported that once-daily administration of valbenazine was well tolerated with a statistically significant improvement in chorea associated with HD compared with placebo, along with substantial clinician- and patient-rated global improvement. The additional data includes an exploratory analysis of valbenazine effects over time, dosages at the end of the study, and detailed information about treatment-emergent adverse events (TEAEs) and safety parameters, such as electrocardiogram (ECG) and laboratory tests.

These data (Poster #2: Valbenazine for the Treatment of Chorea Associated with Huntington Disease: Results from a Phase 3 Trial) will be shared at the 29(th) annual meeting of the Huntington Study Group in Tampa, Florida on November 3--5. The KINECT-HD study met its primary endpoint of change in chorea severity using the Total Maximal Chorea (TMC) score of the UHDRS(R) from screening period baseline to maintenance period. Improvement in the TMC score was significantly greater with valbenazine versus placebo. The secondary endpoints of Clinical Global Impression of Change (CGI-C) Response Status and Patient Global Impression of Change (PGI-C) Response Status also significantly favored valbenazine treatment.

Treatment emergent adverse events, including somnolence, fatigue, fall, and akathisia, were mild to moderate and consistent with the known safety profile of valbenazine.